HER2-Low, HR-Positive, and Triple-Negative Breast Cancer: Expert Training and Real-world Perspectives on Novel HER2-Targeted and TROP-2–Targeted Therapies

This educational series will help healthcare professionals to effectively personalize the care of patients with breast cancer and will provide evidence-based expert perspectives on the implications of recent classification changes in HER2 expression levels, including discussions about TROP-2–targeted therapies for HER2-negative breast cancer with the aim to optimize treatment outcomes for patients with HER2-low, HR-positive, and triple-negative breast cancer. After the education, download the associated slidesets for use in the clinic.

Share

Program Content

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.